Abaloparatide is a PTHrP analog approved for osteoporosis. Explore its mechanism, clinical trial results from ACTIVE, safety profile, and regulatory status.
# Abaloparatide: Mechanism, Clinical Trials & Safety
Abaloparatide is a PTHrP analog approved for osteoporosis. Explore its mechanism, clinical trial results from ACTIVE, safety profile, and regulatory status.
Data-driven content targeting the keyword cluster "abaloparatide" with 1 related keywords and 0 monthly search volume.
Open with a clear definition: abaloparatide is a synthetic analog of parathyroid hormone-related protein PTHrP used in osteoporosis treatment. Briefly mention its approval e.g., FDA for postmenopausal osteoporosis . Avoid clinical recommendations. Provide structural context 34-amino acid peptide, differs from teriparatide at key positions . Include a snippet-friendly definition box.
Explain how abaloparatide binds selectively to the PTH1 receptor, leading to anabolic bone effects increase bone formation . Contrast with teriparatide PTH 1-34 — abaloparatide has higher selectivity for the RG conformation of PTH1R, possibly reducing bone resorption. Use a comparison table for featured snippet potential. Cite preclinical and clinical pharmacodynamic data. No dosing.
Summarize key efficacy endpoints from the pivotal ACTIVE trial N=~2400, 18 months . Report reductions in vertebral fractures ~86% vs placebo and nonvertebral fractures. Include BMD increases at lumbar spine, total hip. Use statistical data without direct recommendation. Note that the trial compared abaloparatide to placebo and teriparatide substudy . Maintain neutral tone.
List common side effects hypercalciuria, nausea, dizziness . Highlight the FDA boxed warning regarding osteosarcoma risk from rodent studies . Emphasize that abaloparatide is not recommended for patients at high risk of osteosarcoma e.g., Paget’s disease, prior radiation . Mention that duration of use is limited to 2 years. No dosing guidance.
State that abaloparatide brand name Tymlos received FDA approval in 2017 for postmenopausal osteoporosis with high fracture risk. Mention EMA approval in 2019. Briefly note that guidelines e.g., AACE/ACE position it as second-line after bisphosphonates or for severe cases. Avoid endorsing any specific therapy.
Expand on the teriparatide comparison initiated earlier. Create a detailed table: structure, mechanism, BMD gains, fracture reduction, side effect profile. Then briefly contextualize abaloparatide among other osteoporosis agents bisphosphonates, denosumab, romosozumab without recommendation. Use internal links to other peptide pages e.g., BPC-157, TB-500 in a 'Further Exploration' sub-section, noting that these peptides are from different therapeutic areas tissue repair, etc. .
Structure as an FAQ section to capture featured snippets. Provide concise, evidence-based answers. Use plain language. Each answer should be 2-3 sentences. Include a question about regulatory status. Avoid any personal advice.
1. BPC-157 tissue repair peptide https://peptideatlas.co/peptides/bpc-157 , Peptide Atlas.
2. TB-500 thymosin beta-4 https://peptideatlas.co/peptides/tb-500 , Peptide Atlas.
3. Semaglutide GLP-1 receptor agonist https://peptideatlas.co/peptides/semaglutide , Peptide Atlas.
4. Tirzepatide dual GIP/GLP-1 receptor agonist https://peptideatlas.co/peptides/tirzepatide , Peptide Atlas.
5. PT-141 bremelanotide https://peptideatlas.co/peptides/pt-141 , Peptide Atlas.
6. Ipamorelin growth hormone secretagogue https://peptideatlas.co/peptides/ipamorelin , Peptide Atlas.
7. CJC-1295 GHRH analog https://peptideatlas.co/peptides/cjc-1295 , Peptide Atlas.
8. GHK-Cu copper peptide https://peptideatlas.co/peptides/ghk-cu , Peptide Atlas.
9. Melanotan II MC1R agonist https://peptideatlas.co/peptides/melanotan-ii , Peptide Atlas.
10. LL-37 cathelicidin antimicrobial peptide https://peptideatlas.co/peptides/ll-37 , Peptide Atlas.
This resource is for education and research context only. It does not provide medical advice, diagnosis, treatment instructions, personal dosing guidance, or vendor recommendations.